Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Nutriband (NTRB) announced the completion of commercial manufacturing process scale-up with Kindeva for Aversa™ Fentanyl, an abuse-deterrent fentanyl patch combining Nutriband’s technology with Kindeva’s FDA-approved patch. The next step involves manufacturing clinical supplies and filing an IND application with the FDA to initiate human abuse liability clinical studies. Aversa Fentanyl, with potential peak annual US sales of $80 million to $200 million, aims to be the first abuse-deterrent pain patch on the market, addressing the abuse, misuse, and accidental exposure risks associated with transdermal fentanyl.

Analysis

Nutriband Inc. has achieved a significant milestone by completing the commercial manufacturing process scale-up for its lead product, Aversa™ Fentanyl, in collaboration with Kindeva. This development integrates Nutriband's Aversa™ abuse-deterrent technology with Kindeva’s existing FDA-approved fentanyl patch, manufactured at Kindeva's US-based facility. This successful scale-up is a critical step, affirming the compatibility of the Aversa™ technology with established transdermal patch manufacturing processes and paving the way for an eventual New Drug Application (NDA) filing. The company is now preparing to manufacture clinical supplies and file an Investigational New Drug (IND) application with the FDA to initiate a human abuse liability clinical study. Nutriband's CEO, Gareth Sheridan, highlighted this as an important progression towards a commercially viable product, with Aversa™ Fentanyl potentially becoming the first abuse-deterrent pain patch on the market. The product targets a substantial market, with projected peak annual US sales ranging from $80 million to $200 million, based on a 2022 market analysis report, and Nutriband has ambitions for global market reach. The Aversa™ technology is underpinned by a broad international intellectual property portfolio, with patents granted in 46 countries.

Key Decisions for Investors

• Investors should recognize the completion of the commercial manufacturing scale-up for Aversa™ Fentanyl as a material de-risking event that advances a key product candidate towards potential regulatory submission and commercialization.
• Upcoming catalysts to monitor closely include the filing of the Investigational New Drug (IND) application with the FDA and the subsequent initiation and results of the human abuse liability clinical study, which will be pivotal for future valuation.
• The projected peak annual US sales of $80 million to $200 million for Aversa™ Fentanyl present a significant revenue opportunity; however, this potential should be weighed against the inherent clinical development timelines, regulatory hurdles, and financial resources required for a company at this stage of development.